The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 337:1159-1161 October 16, 1997 Number 16
NextNext

Equivalence Trials

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
In the typical two-group clinical trial with outcomes of either success or failure, investigators are interested in finding out whether an innovative treatment, T, reduces the frequency of failure relative to standard therapy, S. If pT and pS are used to represent the respective frequencies, this question can be answered by testing the null hypothesis of equal efficacy, H0: pT = pS, against the alternative hypothesis of superiority, HA: pT < pS. If the null hypothesis can be rejected in favor of the alternative hypothesis, we conclude that the new therapy is superior to standard therapy. . . . [Full Text of this Article]

References


Related Letters:

Thrombolytic Therapy for Myocardial Infarction
Frei S., Brophy J., Andreotti F., Thron C. D., Topol E. J., Califf R. M., Wilcox R., The GUSTO III Steering Committee , Van de Werf F., The COBALT Investigators , Ware J. H., Antman E. M.
Extract | Full Text  
N Engl J Med 1998; 338:545-548, Feb 19, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.